RxDoctor Payments Data

David Buras, MD

Internal Medicine · College Station, TXNPI 1245301373

Payments from drug & device makers

$11,853in general payments, 2019–2025

Across 729 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$1K
  • Lilly USA, LLC$880
  • Amgen$746
  • Pfizer$655
  • Bayer$576
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$11,57998%
  • Education$2742%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,853 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$342,324
Medicare patients
577
Services billed
4,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide507$646,765
MounjaroTirzepatide261$310,828
JardianceEmpagliflozin211$209,394
EliquisApixaban199$165,249
TrulicityDulaglutide120$137,944
CopaxoneGlatiramer Acetate23$132,853
FarxigaDapagliflozin Propanediol91$87,928
VascepaIcosapent Ethyl93$52,557
Icosapent Ethyl135$48,734
XareltoRivaroxaban41$42,567
Tresiba Flextouch U-200Insulin Degludec46$38,742
MyrbetriqMirabegron47$29,500
JanuviaSitagliptin Phosphate39$23,823
MultaqDronedarone Hcl17$19,707
KerendiaFinerenone25$19,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$3,196$646,765507 claims
Lilly USA, LLCMounjaro, Trulicity$880$448,772381 claims
Boehringer IngelheimJardiance$390$209,394211 claims
PfizerEliquis, Premarin$655$173,092221 claims
AstraZenecaFarxiga$353$87,92891 claims
Johnson & JohnsonXarelto, Invokana$530$53,92155 claims
Astellas Pharma US IncMyrbetriq, Veozah$424$35,96559 claims
MerckJanuvia, Lagevrio (Eua)$93$31,15950 claims
GSKTrelegy Ellipta, Breo Ellipta$187$25,25046 claims
Sanofi-aventis U.S. LLCMultaq$266$19,70717 claims
BayerKerendia$576$19,47325 claims
Esperion Therapeutics, Inc.Nexlizet$79$13,13927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in College Station

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →